22-10-2021, 08:38 AM
Pfizer and its German partner BioNTech yesterday said that data from a Phase III trial demonstrated high efficacy of a booster dose of their Covid-19 vaccine against the virus, including the Delta variant.
They said a trial of 10,000 participants aged 16 or older showed 95.6 per cent effectiveness against the diseases, during a period when the Delta strain was prevalent.
The study also found that the booster shot had a favorable safety profile....
Part of an article found in today's The New Paper
They said a trial of 10,000 participants aged 16 or older showed 95.6 per cent effectiveness against the diseases, during a period when the Delta strain was prevalent.
The study also found that the booster shot had a favorable safety profile....
Part of an article found in today's The New Paper